Please login to the form below
New cancer meds and drug extensions top CHMP recommendations
Drugs for rare disease, oncology and diabetes top regulator’s endorsements
Gilead's Harvoni gains NICE yes - but won't face funding delay
Unlike the company's Sovaldi, which won’t be paid for until the summer
J&J sells Cordis unit to Cardinal Health for $1.94bn
Marks J&J’s exit from the cardiovascular stent market
Complaints about UK medical advertising drop
And this year the MHRA will be vetting adverts to promote a ‘right first time’ approach
GSK public-private partnership CTTV names director
Centre for Therapeutic Target Validation launched last year
Novartis and GSK complete oncology and vaccines swap
Follows Swiss company's decision to divest its BRAF and MEK inhibitors to Array BioPharma
Amgen's Kyprolis tops Velcade in myeloma trial
Amgen hoping to topple Takeda’s $2bn a year drug
Sanofi’s Lantus follow-up nears European approval
CHMP backing for Toujeo follows hot on the heels of its US approval by the FDA
Does 'trust leadership' feature in your strategy?
Pharma companies wanting to be more patient-focused will need to develop their people skills
-
2015: A year of promise and connectivityHow could technology impact healthcare in this year and what will be the key trends to follow?
-
Future gazing: What does 2015 hold for NICE?Undermined by the CDF, the Institute is set to face a number of challenges this year
-
Greater Manchester to control its share of the NHS budgetThe north-west English region accounts for 5% of the country's health spending
-
Jinarc backed for European approval in rare kidney diseasePositive opinion for Otsuka comes just before rare disease awareness day
-
UCB boosted by core medicines growthFirm’s new chief executive 'excited' by his company’s next batch of medicines
-
Sovaldi-Daklinza combo cures hep C in co-infected HIV patientsPhase III trial of BMS and Gilead antivirals cured 97% of patients
-
Bayer's Eylea cleared for wider use in EuropeMacular oedema treatment reached €759m in sales last year
-
Gilead's Sovaldi wins NICE approval but faces access delayThe Institute also recommends Janssen's hepatitis C drug Olysio
-
Sanofi gets green light for Lantus follow-up ToujeoOnce-daily basal insulin gains FDA approval for diabetes
Latest appointments
-
Publicis Healthcare names North America group presidentAlexandra von Plato to take up the role
-
Ex Sanofi boss joins Boston start-upChris Viehbacher joins other industry veterans as the newest board member of PureTech
-
Cidara Therapeutics makes senior appointmentsPaul Daruwala and James Balkovec join the biotech
-
Peter Nightingale appointed as chair of new MHRA committeeWas formerly president of the Intensive Care Society
-
UCB CEO elected to the Ministerial Industry Strategy GroupJean-Christophe Tellier assumed the role of CEO on January 1
Featured jobs
- Experienced Medical Writer MILAN – ITALY – Medical Education – R...
-
Excellent Remuneration & Relocation Assistance
- Senior Medical Writer
-
Competitive Salary Offered
DGH Recruitment
- Associate Project Director – Meetings Management - Reading, Berk...
-
Competitive + excellent benefits
- Assistant Editor – Clinical Pharmacy: The Pharmaceutical Journal...
-
Competitive Salary Offered
- Account Executive and Senior Account Executive NEEDED for FUN &...
-
Bonus + Benefits
- Director – Client Engagement – Brand Team - Reading, Berkshire...
-
Senior level salary + comprehensive benefits
- Account Manager & Senior Account Manager – Medical Communica...
-
£33000 - £48000 + BONUS + BENEFITS
- FREELANCE!! Account Manager / Senior Account Manager – TOP 5 Hea...
-
VERY COMPETITIVE DAY RATE
- Healthcare PR Account Manager, Internal Communications
-
c£30-35,000 according to skills and experience
- Business Unit Director – Consumer Healthcare Advertising – South...
-
Very lucrative remuneration on offer
- AM or Senior Account Manager – Digital – Healthcare Advertising ...
-
EXTENSIVE PACKAGE AVAILABLE
Subscribe to our email news alerts
- Indian generics firm GVK set to be hit with European sales ban
- Boehringer in breach over beer drinking, lederhosen presentation
- Pharma firms violate marketing regulations every week, claims study
- Advagraf shows survival increase for liver transplant patients
- BMS buys immunotherapy specialist Flexus in $1.2bn deal
- CRF Health partners with Vodafone on communication platform
- Transforming times at AstraZeneca
- Merck's MS drug Rebif resisting competition
- New cancer meds and drug extensions top CHMP recommendations
- Gilead's Harvoni gains NICE yes - but won't face funding delay
- J&J sells Cordis unit to Cardinal Health for $1.94bn
- Publicis Healthcare names North America group president
PMHub
Liberation Unlimited
'Progressive', 'cutting edge' – words used to describe Liberation Unlimited. We believe looking forward is essential to delivering successful and...
Latest intelligence
- Growing influence of pharmacists in the sale of Rx and OTC medicines
- Find out how the changes within pharmacy have affected their influence over the sales of RX and OTC medicines in this whitepaper....
- Drivers of 2014′s Soaring Drug Approvals
- The FDA & EMA approved a chart-topping number of new drugs in 2014. Read more in our White Paper about the responsibility this growing approval success will put on future...
- Russian innovation at the crossroads
- Despite improvements, investors face rising risks...
Quick links
